Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

ACCORD BIOPHARMA, INC.

UEI: M3PMHL5VML74CAGE: 98XD1

ACCORD BIOPHARMA, INC. is a federal contractor, registered under UEI M3PMHL5VML74 and CAGE code 98XD1. It has been awarded $19,420,700 in federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

M3PMHL5VML74

CAGE Code

98XD1

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationForeign Owned

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ACCORD BIOPHARMA, INC. specializes in the manufacturing of pharmaceutical preparations, with a demonstrated focus on producing drugs, pharmaceuticals, and hematology-related products for federal healthcare systems. The company operates within the highly regulated biopharmaceutical manufacturing spac...

ACCORD BIOPHARMA, INC. specializes in the manufacturing of pharmaceutical preparations, with a demonstrated focus on producing drugs, pharmaceuticals, and hematology-related products for federal healthcare systems. The company operates within the highly regulated biopharmaceutical manufacturing space, ensuring compliance with cGMP standards and quality control protocols required for federal supply chains. Their technical expertise lies in the formulation, packaging, and distribution of finished dosage forms, particularly those used in clinical and long-term care settings. While specific product lines are not detailed, their work under the Federal Supply Schedule suggests a capability to deliver standardized, high-volume pharmaceuticals with consistent batch integrity and regulatory traceability. The contractor has established a direct relationship with the Department of Veterans Affairs, supplying pharmaceuticals through its Federal Supply Schedule program. This indicates a proven ability to meet VA’s stringent requirements for drug procurement, including formulary alignment, therapeutic equivalence, and just-in-time logistics for veteran care facilities. Their engagement with the VA underscores a niche positioning in supporting chronic disease management and hematologic therapies within the veteran population. ACCORD BIOPHARMA’s primary industry focus is NAICS 325412—Pharmaceutical Preparation Manufacturing—where they operate as a specialized producer of finished drug products rather than active pharmaceutical ingredients. This vertical specialization positions them as a contract manufacturer serving government health systems that require reliable, compliant, and scalable pharmaceutical supply. Their market role centers on bridging the gap between bulk drug synthesis and end-user delivery in federal healthcare environments. As a small business structured as a 2L entity based in Raleigh, North Carolina, ACCORD BIOPHARMA operates with a lean, focused model. The company holds no formal government certifications, but its successful award under the VA’s FSS program demonstrates its capacity to navigate federal procurement regulations and maintain quality systems aligned with FDA and GPO standards. Their geographic presence supports efficient distribution to eastern U.S. federal medical facilities.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

4

All time

Active

1

Currently performing

Completed

3

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with ACCORD BIOPHARMA, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ACCORD BIOPHARMA, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in ACCORD BIOPHARMA, INC.'s top NAICS codes and agencies

NAICS: 325412
New
Federal
6505--Nitroglycerin Patches
Solicitation # 36E79727R0010
The Department of Veterans Affairs National Acquisition Center is initiating an unrestricted procurement for Nitroglycerin Patches under solicitation 36E79727R0010. This contract will serve the VA, including Consolidated Mail Order Pharmacies and Option 2 State Veterans Homes, as well as the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The award will be granted to a single responsible offeror capable of providing an uninterrupted source of supply for a one-year base period followed by four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. The procurement covers four strengths of Nitroglycerin patches (0.1 mg, 0.2 mg, 0.4 mg, and 0.6 mg), with estimated annual usage ranging from 2,213 to 10,044 boxes. All patches must be supplied in boxes of 30 and must feature barcoding on both the individual patch and the outside box. Strict labeling requirements apply: the contractor must provide a unique NDC number, and their label must be the only one on the product, without being affixed over another label. Additionally, the labels must allow VA labels to adhere securely over them. This solicitation will be issued in commercial item format per FAR Part 12, with a tentative issuance date of December 1, 2026, and a closing date of December 15, 2026.
Nac Pharmaceuticals (36E797)

POSTED

about 16 hours ago

DEADLINE

in 8 days
View Details
NAICS: 325412
New
International
Calcium Trisodium Pentetate (Ca-DTPA) ampoules
Solicitation # W6369-27-A062
The Department of National Defence, through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, is seeking the supply of Calcium Trisodium Pentetate (Ca-DTPA) ampoules to treat Canadian Armed Forces personnel exposed to radioactive contamination involving transuranic elements. The required product must be a sterile solution for intravenous injection containing 1,000 mg to 1,055 mg of active ingredient in a 5 mL ampoule, with a minimum shelf-life of 36 months from the date of manufacture. To ensure consistency with existing stockpiles, the product must adhere to specific packaging and labelling requirements and hold valid marketing authorization from Health Canada, the FDA, the EMA, or an EU member state. The procurement is being conducted via an Advance Contract Award Notice, with Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG identified as the sole known supplier capable of meeting the technical and clinical requirements. The contract is anticipated to run from the award date until March 31, 2031, with an estimated total value of 47,500 CAD. The firm requirement consists of 750 ampoules delivered in three annual increments of 250, starting no later than March 1, 2027, and ending by March 1, 2029. Additionally, the contract includes an option for up to 500 more ampoules exercisable throughout the contract period. This procurement is subject to the Canadian Free Trade Agreement and is not subject to set-asides or the Procurement Strategy for Indigenous Business.
Department of National Defence

POSTED

about 23 hours ago

DEADLINE

in 15 days
View Details
NAICS: 325412
New
DIBBS
BISMUTH SUBSALICYLATE
Solicitation # SPE2DP-27-T-0266
This solicitation, issued by the Defense Logistics Agency (DLA) under number SPE2DP-27-T-0266, is a small business set-aside for the procurement of 55 packages of over-the-counter, sugar-free Bismuth Subsalicylate tablets. Each tablet must contain 262 mg of Bismuth Subsalicylate and 140 mg of Calcium, with each unit of issue consisting of 48 individually sealed tablets. The product has a total shelf life of 36 months, and a minimum of 31 months must remain at the time of receipt by the first government activity. To maintain product integrity, the supplies must be protected from excessive heat exceeding 104 degrees Fahrenheit or 40 degrees Celsius. The contract specifies that packaging and packing must be commercial, with each unit in a sealed container and shipped in suitable commercial exterior containers to ensure safe delivery. Marking and labeling must adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and preservation must follow MIL-STD-2073-1E. Delivery is required FOB Destination to the DC ARNG MED DET in Washington, DC, with a delivery lead time of 20 days. Inspection and acceptance will occur at the destination. The procurement incorporates various FAR and DFARS clauses, including requirements for safeguarding covered defense information, NIST SP 800-171 assessment, and the Buy American Act. Invoicing must be processed electronically through the Wide Area Workflow system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days
View Details